We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sign up to read this article for FREE!

After signing up, you'll start to receive regular news updates from us.

Galapagos Names Director of Medicinal Chemistry at Biofocus

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Galapagos has announced that Dr. Angus MacLeod has joined Galapagos' service division BioFocus as Director of Medicinal Chemistry.

Dr. MacLeod was previously with Merck Sharp & Dohme where he spent 21 years in medicinal chemistry, most recently as Senior Director, Medicinal Chemistry.

Dr. MacLeod has impressive track records in the industry contributing to a number of programs leading to clinical candidates, including the Substance P antagonist program that resulted in the marketed product aprepitant (Emend®), and a GABA receptor modulator program. Dr. MacLeod is author/inventor on 100 publications and patents.

Dr. Chris Newton, Senior VP BioFocus commented, "Dr. MacLeod's appointment is a big win for BioFocus."

"The most critical factors in converting a chemical lead to a clinical candidate drug are tenacity, experience, and multi-disciplinary team leadership, which Dr. MacLeod has in abundance."

"Dr. MacLeod joins BioFocus' recently appointed Director of Biology, Dr. Iain James, who joined us after 17 years with Novartis."

"Together, Dr. MacLeod and Dr. James head up a most impressive drug discovery team, which is available to BioFocus' worldwide clients."